Der var en signifikant lavere forekomst af arytmier hos patienter i behandling med Ranexa (74%) sammenlignet med placebo (83%), herunder ventrikulær takykardi ≥ 8 slag (5% mod 8%).
There was a significantly lower incidence of arrhythmias in patients treated with Ranexa (74%) versus placebo (83%), including ventricular tachycardia ≥ 8 beats (5% versus 8%).